CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE). Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 29
Healthy Volunteers: f
View:

• Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.

• Patient age must be 12-29 years, inclusive, at time of enrollment.

• Meeting ACR/EULAR Classification Criteria for SLE

• ANA positive \> 1:80 and/or double-stranded DNA (dsDNA) positive

• Active (refractory) disease, despite at least three months of conventional therapy, defined as follows:

• a. Lupus nephritis subjects must meet both the following criteria: i. ISN/RPS active nephritis Class III/IV +/- V lupus nephritis diagnosed by biopsy within past 12 months.

⁃ ii. Persistent and clinically significant: ≥2 measurements with urine protein on first morning sample with either of the following:

• \> 1000mg/g creatinine

• \> 500 mg/g creatinine associated with renal dysfunction or low albumin.

• \> 500 mg/g creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg/day or 0.15mg/kg/day, whichever is lower, due to active disease.

⁃ 6\. Patients must have had at least 3 months conventional therapy defined as:

• Conventional induction immunosuppressive agent(s) (mycophenolate mofetil or cyclophosphamide), and

• At least one additional therapy:

⁃ i. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor, others) 7. Adequate organ function status

• Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.

• Hepatic: Transaminases \< 5x upper limit of normal and serum conjugated (Direct) bilirubin \<1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.

• Cardiac: Shortening fraction \> 28%, left ventricular ejection fraction \>45%, and no evidence of severe pulmonary hypertension

• Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and \<Grade 3 hypoxia; DLCO ≥40% (corrected for anemia and/or VA volume) if PFTs are clinically appropriate as determined by the treating investigator.

• 8\. Subjects of reproductive potential must agree to use acceptable birth control methods.

Locations
United States
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Contact Information
Primary
Caitlin Elgarten, MD
elgartenc@chop.edu
267-425-7964
Backup
Melissa Varghese
verghesem@chop.edu
845-553-5358
Time Frame
Start Date: 2025-05-06
Estimated Completion Date: 2030-02-28
Participants
Target number of participants: 24
Treatments
Experimental: CART19
Participants will receive the study product. CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.
Sponsors
Leads: Children's Hospital of Philadelphia

This content was sourced from clinicaltrials.gov